No Data
No Data
Pasithea Therapeutics Announces SRC Recommended Proceeding to Cohort 4
Express News | Pasithea Therapeutics Corp - Src Recommends Escalation to 15Mg Dose Level
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation From Its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Express News | Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced Cancer
10-Q: Q3 2024 Earnings Report
Pasithea Therapeutics Files to Sell 3.74M Shares of Common Stock for Holders
No Data
No Data